Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
종목 코드 DARE
회사 이름Dare Bioscience Inc
상장일Apr 10, 2014
CEOMs. Sabrina Martucci Johnson
직원 수21
유형Ordinary Share
회계 연도 종료Apr 10
주소3655 Nobel Dr Ste 260
도시SAN DIEGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92122-1050
전화18589267655
웹사이트https://www.darebioscience.com/
종목 코드 DARE
상장일Apr 10, 2014
CEOMs. Sabrina Martucci Johnson
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음